Last updated on June 2018

Afrezza Safety and Pharmacokinetics Study in Pediatric Patients


Brief description of study

Primary Objective:

-To assess the safety and tolerability of Afrezza in children ages 4 to 17 years with type 1 diabetes mellitus (T1DM).

Secondary Objectives:

  • To assess the ability to titrate the prandial and supplemental doses of Afrezza at each meal.
  • To assess pharmacokinetics (PK) following a prandial dose of Afrezza in children ages 4 to 17 years with T1DM.

Detailed Study Description

The patients are expected to participate in the study for approximately 6 to 8 weeks from Screening to final follow-up visit.

Clinical Study Identifier: NCT02527265

Contact Investigators or Research Sites near you

Start Over

For site information, call or ...

Investigational Site 637
Aurora, CO United States
  Connect »

For site information, call or ...

Investigational Site 635
New Haven, CT United States
  Connect »

For site information, call or ...

Investigational Site 636
Gainesville, FL United States
  Connect »

For site information, call or ...

Investigational Site 002
Atlanta, GA United States
  Connect »

For site information, call or ...

Investigational Site 639
Atlanta, GA United States
  Connect »

For site information, call or ...

Investigational Site 642
Atlanta, GA United States
  Connect »

For site information, call or ...

Investigational Site 638
Baltimore, MD United States
  Connect »

For site information, call or ...

Investigational Site 640
Philadelphia, PA United States
  Connect »

For site information, call or ...

Investigational Site 641
Memphis, TN United States
  Connect »

For site information, call or ...

Investigational Site 643
Tampa, FL United States
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.